Ryanodine

(HB1320)
Technical documents: SDS CoA Datasheet
3  Reviews
Top Reviews:
100% of 100
Add Your Review

Product overview

Name Ryanodine
Purity >98%
Description Potent Ca2+ release inhibitor
Write Your Own Review
You're reviewing:Ryanodine
Rate this item:

Images

Ryanodine product vial image | Hello Bio

Biological Data

Biological description Potent Ca2+ release inhibitor. Inhibits release from the cardiac and skeletal muscle sarcoplasmic reticulum (IC50 values are 2.8 and 10 nM respectively). Shows actions to slow arrhythmia development in heart failure.

Solubility & Handling

Storage instructions -20°C (desiccate)
Solubility overview Soluble in ethanol (10mM) and in DMSO (25mM)
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Purity >98%
Chemical name 1H-Pyrrole-2-carboxylic acid, (3S,4R,4aR,6S,7S,8R,8aS,8bR,9S,9aS) -dodecahydro-4,6,7,8a,8b,9a-hexahydroxy-3,6a,9-tri methyl-7-(1-methylethyl)-6,9-methanobenzo[1,2]pent aleno[1,6-bc]furan-8-yl ester
Molecular Weight 493.55
Chemical structure Ryanodine  [15662-33-6] Chemical Structure
Molecular Formula C25H35NO9
CAS Number 15662-33-6
PubChem identifier 11317883
SMILES CC(C)[C@@]6(O)C(OC(=O)c1cccn1)[C@]2(O)[C@@]5(O)[C@@]34O[C@@](O)(C[C@@]2(C)[C@@]4(O)CC[C@H](C)[C@H]3O)[C@]56C
Source Extracted from ryania speciosa
InChi InChI=1S/C25H35NO9/c1-12(2)22(31)17(34-16(28)14-7-6-10-26-14)23(32)18(4)11-21(30)19(22,5)25(23,33)24(35-21)15(27)13(3)8-9-20(18,24)29/h6-7,10,12-13,15,17,26-27,29-33H,8-9,11H2,1-5H3/t13-,15+,17+,18-,19+,20-,21-,22+,23+,24+,25+/m0/s1
InChiKey JJSYXNQGLHBRRK-SFEDZAPPSA-N

References for Ryanodine

References are publications that support the biological activity of the product
  • Effects of sarcolemmal Ca(2+) entry, ryanodine function, and kinase inhibitors on a rabbit model of heart failure.

    Kijtawornrat A et al (2010) Int Heart J 51(4) : 285-90.
  • Ryanodine modification of RyR1 retrogradely affects L-type Ca(2+) channel gating in skeletal muscle.

    Bannister RA et al (2009) J Muscle Res Cell Motil 30(5-6) : 217-23.
  • The pharmacology of ryanodine and related compounds.

    Sutko JL et al (1997) Pharmacol Rev 49(1) : 53-98.

3 Item(s)